Form 4: Spruce Biosciences Director Acquires 30,000 Stock Options

Director Daniel K. Spiegelman acquired 30,000 stock options in Spruce Biosciences, Inc. on May 22, 2024.

Summary

• On May 22, 2024, Daniel K. Spiegelman, a director of Spruce Biosciences, Inc., acquired 30,000 stock options.
• The options have an exercise price of $0.7511.
• The options vest on the first anniversary of the grant date or fully vest at the 2025 annual stockholder meeting, contingent on continuous service.
• The options will also vest in full upon a Change in Control as defined in the 2020 Equity Incentive Plan.
• The expiration date for the options is May 21, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally indicates confidence in the company's future, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is tied to continued service and a potential change in control, suggesting an incentive for the director to remain engaged with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in biotech companies like Spruce Biosciences.
• Comparable companies such as Crinetics Pharmaceuticals or Neurocrine Biosciences also utilize stock options to align the interests of management with those of shareholders.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term value creation.

Stakeholder Impact

• The acquisition of stock options by a director can have a slightly positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates